NeuroSense GM Hagit Binder discloses share and option stakes

NeuroSense Therapeutics Ltd. officer Hagit Binder, serving as General Manager, has filed a Form 3 showing her current equity interests in the company.

Accepted by SEC EDGAR 03/18/2026 - 03:35 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. officer Hagit Binder, serving as General Manager, has filed a Form 3 showing her current equity interests in the company. She directly holds ordinary shares listed in several line items, including 12,836 shares, 32,000 shares and 266,970 shares.

Binder also holds options to purchase 36,000 ordinary shares at an exercise price of $1.9900 per share, expiring on October 12, 2032; these options are fully vested and exercisable. In addition, she holds 10,000 restricted share units that are scheduled to vest on April 1, 2026. Certain plan-related securities are held through a trustee to qualify for tax benefits under Israeli law.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Binder Hagit

Role General Manager

Type	Security	Shares	Price	Value
Holding	Options to Purchase Ordinary Shares	--	--	--
Holding	Ordinary Shares	--	--	--
Holding	Ordinary Shares	--	--	--
Holding	Ordinary Shares	--	--	--
Holding	Restricted Share Units	--	--	--

Holdings: Options to Purchase Ordinary Shares — 36,000 contracts (Direct); Ordinary Shares — 311,806 shares (Direct); Restricted Share Units — 10,000 shares (Direct)

Footnotes (4)

1. F1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.
2. F2. These restricted shares vest in accordance with the following vesting schedule: (i) 75% vest on April 16, 2027, and (ii) the remaining portion shall vest on October 16, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
3. F3. The restricted share units shall vest on April 1, 2026
4. F4. These options are fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does NeuroSense (NRSN) General Manager Hagit Binder report on this Form 3?

Hagit Binder reports her existing equity interests in NeuroSense, including direct holdings of ordinary shares, vested stock options and restricted share units. The filing outlines her current ownership position rather than new buying or selling activity, giving investors transparency into an officer’s stake in the company.

How many NeuroSense (NRSN) options does Hagit Binder hold and at what price?

Hagit Binder holds options to purchase 36,000 NeuroSense ordinary shares at an exercise price of $1.9900 per share. These options are fully vested and exercisable and expire on October 12, 2032, providing her long-term equity exposure aligned with the company’s performance.

What ordinary share holdings does Hagit Binder disclose in NeuroSense (NRSN)?

The Form 3 lists several direct ordinary share positions for Hagit Binder, including 12,836 shares, 32,000 shares and 266,970 shares. These line items together describe her direct ownership of NeuroSense equity, offering more clarity on how much common stock this executive currently holds.

When do Hagit Binder’s NeuroSense (NRSN) restricted share units vest?

Hagit Binder’s restricted share units are scheduled to vest on April 1, 2026. Once vested, these 10,000 units convert into ordinary shares, further increasing her direct equity stake and linking a portion of her compensation to NeuroSense’s long-term share performance.

Why are some NeuroSense (NRSN) securities held through a trustee for Hagit Binder?

Certain securities issued to Hagit Binder under NeuroSense’s 2018 Share Incentive Plan are registered in a trustee’s name to qualify for Israeli tax benefits under Section 102. This structure is a legal and tax requirement and does not change her underlying economic interest in those awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Binder Hagit

(Last) (First) (Middle)

C/O NEUROSENSE THERAPEUTICS LTD.

11 HAMENOFIM STREET, BUILDING B

(Street)

HERZLIYA 4672562

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NeuroSense Therapeutics Ltd. [ NRSN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Manager

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	12,836	D
Ordinary Shares(1)	32,000	D
Ordinary Shares(1)(2)	266,970(2)	D
Restricted Share Units(1)(3)	10,000(3)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares(1)(4)	11/17/2022	10/12/2032	Ordinary Shares	36,000(4)	$1.99	D

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.

2. These restricted shares vest in accordance with the following vesting schedule: (i) 75% vest on April 16, 2027, and (ii) the remaining portion shall vest on October 16, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.

3. The restricted share units shall vest on April 1, 2026

4. These options are fully vested and exercisable.

	/s/ Hagit Binder	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)